ad 5075 has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, T; Ikeda, H; Meguro, K; Mizuno, K; Momose, Y; Sohda, T | 1 |
| Berger, GD; Berger, J; Biswas, C; Cullinan, CA; Doebber, TW; Elbrecht, A; Hayes, NS; Leibowitz, MD; Li, Y; Marquis, R; Moller, DE; Mosley, R; Sahoo, SP; Santini, C; Smith, RG; Tanen, M; Tolman, RL; Ventre, J; Wu, MS; Zhang, B; Zhou, G | 1 |
2 other study(ies) available for ad 5075 and Alloxan Diabetes
| Article | Year |
|---|---|
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Mice; Pioglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 1992 |
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.
Topics: Adipocytes; Animals; Blood Glucose; Cell Differentiation; Cell Line; Diabetes Mellitus, Experimental; Humans; Ligands; Mice; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 1999 |